|
|
|
24270 |
 |
Re:... April 23 -25--NASH Summit NAVB headline: "YES, YES, YES..CAN TARGET/LOCALIZE/IMAGE M1" and M2 |
GN |
Iwinshortslose2 |
|
0 |
4/23/2018 6:32:34 PM |
|
| | |
|
24269 |
|
Re:... April 23 -25--NASH Summit NAVB headline: --MG Outline-localization in humans and animals and animal therapeutics targeting ..15 minutes, plus 15 minute Q&A split |
GN |
moneyonomics |
|
4 |
4/23/2018 6:20:42 PM |
|
| | |
|
24268 |
|
Re:... April 23 -25--NASH Summit NAVB headline: "YES....CAN TARGET/LOCALIZE/IMAGE M1" and M2 |
GN |
moneyonomics |
|
4 |
4/23/2018 3:36:29 PM |
|
| | |
|
24267 |
|
Stock is run by losers |
GN |
NEOP INVESTOR |
Strong Sell |
0 |
4/23/2018 10:48:41 AM |
|
| | |
|
24266 |
|
Reverse Split votes count - send me your shares count and decision y/n/u |
GN |
GoTrump |
|
2 |
4/23/2018 9:31:41 AM |
|
| | |
|
24265 |
|
Support for macrophage science: M. McGrath, MD, et al file patent application for treating and biomarker identification in certain macrophage related diseases. No claim on CD206/209, broad claim for inflammatory factors Interleukins/cytokines in TAMS... |
GN |
moneyonomics |
|
0 |
4/22/2018 6:50:15 PM |
|
| | |
|
24264 |
|
Re: Facts: In 5 year period from 2013 thru 2017 re-engineered Development/R&D spending for Manocept/Macrophage up by a nearly 500% increase, up from $504k to $2.98mm, while cutting total Dev/R&D by $12.3mm or 78% ($15.6mm to $3.3mm-before credits) |
GN |
Iwinshortslose2 |
|
0 |
4/22/2018 5:34:00 PM |
|
| | |
|
24263 |
|
Re: Facts: In 5 year period from 2013 thru 2017 re-engineered Development/R&D spending for Manocept/Macrophage up by a nearly 500% increase, up from $504k to $2.98mm, while cutting total Dev/R&D by $12.3mm or 78% ($15.6mm to $3.3mm-before credits) |
GN |
Iwinshortslose2 |
|
0 |
4/22/2018 5:31:52 PM |
|
| | |
|
24262 |
|
Re: Facts: In 5 year period from 2013 thru 2017 re-engineered Development/R&D spending for Manocept/Macrophage up by a nearly 500% increase, up from $504k to $2.98mm, while cutting total Dev/R&D by $12.3mm or 78% ($15.6mm to $3.3mm-before credits) |
GN |
dwdinvesting |
|
1 |
4/22/2018 5:23:15 PM |
|
| | |
|
24261 |
|
Dr. Toby Mauer contact on NAVB KS trials and co author with McGrath on several macrophage/KS studies.. Feb 2018 video"....KS resurfacing..latent T-Cells hiding out in a "hidden sanctuary" in lymph nodes, etc. leading to inflammation... |
GN |
moneyonomics |
|
1 |
4/22/2018 4:45:14 PM |
|
|
|
|
|
|
.
